Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | TDP2 | O95551 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20819423 | 0.85 | HPGDS (0.51) | TDP1TDP2NSD2ABL1PLCG1 | |
| SCHEMBL1919495 | 0.81 | HPGDS (0.52) | BRD4HPGDSLTA4HADRA1AADRA1D | |
| SCHEMBL362411 | 0.80 | CASP6 (0.35) | TDP1TDP2NSD2ABL1PLCG1 | |
| SCHEMBL362412 | 0.80 | CASP6 (0.38) | TDP1TDP2NSD2ABL1PLCG1 | |
| SCHEMBL15951008 | 0.78 | CYP2A6 (0.46) | TDP1BRD4HPGDSLTA4HKDM4E | |
| SCHEMBL20599370 | 0.78 | PIN1 (0.43) | MEN1KMT2ABRD4HPGDSLTA4H | |
| SCHEMBL31734567 | 0.78 | BRD4 (0.41) | TDP1TDP2NSD2ABL1PLCG1 | |
| SCHEMBL22557217 | 0.78 | HPGDS (0.40) | TDP1TDP2NSD2ABL1PLCG1 | |
| SCHEMBL30792106 | 0.78 | MAP4K4 (0.44) | BRD4HPGDSLTA4HADRA1AADRA1D | |
| SCHEMBL26259967 | 0.77 | BRD4 (0.53) | TDP1GAABRD4HPGDSLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2036181-A | — | — | None | — | — | JP | disclosed |
| EP-2264005-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRIN COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2015-12-02 | — | — | EP | disclosed |
| US-8518928-B2 | Therapeutic compounds | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-08-27 | — | — | US | disclosed |
| US-8309753-B2 | Method for producing optically active cyanohydrin compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20120071527-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-03-22 | — | — | US | disclosed |
| US-8093235-B2 | Macrocyclic compounds which stabilize G-Quadruplex DNA and RNA | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110034718-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRIN COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2264005-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRIN COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2010-12-22 | — | — | EP | disclosed |
| JP-2009256262-A | MANUFACTURING METHOD OF OPTICALLY ACTIVE CYANOHYDRIN COMPOUND | SUMITOMO CHEMICAL CO LTD | 2009-11-05 | — | — | JP | disclosed |
| EP-2079704-A2 | THERAPEUTIC COMPOUNDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20090156627-A1 | THERAPEUTIC COMPOUNDS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-06-18 | — | — | US | disclosed |
| WO-2007127173-A2 | THERAPEUTIC COMPOUNDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2007-11-08 | — | — | WO | disclosed |
| US-5994556-A | Bis(ortho-diarylphosphinophenyl)-tetrahydro-bi(1,3-oxazole) and a preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 1999-11-30 | — | — | US | disclosed |
| JP-H0236181-A | ASYMMETRIC BISOXAZOLYLPYRIDINE DERIVATIVE AND PRODUCTION THEREOF | MITSUI TOATSU CHEM INC | 1990-02-06 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156627-A1 | THERAPEUTIC COMPOUNDS | TOP2B, DDB1, RECQL | TDP1 96/4885TDP2 250/4885NSD2 430/4885 |
| US-20120071527-A1 | THERAPEUTIC COMPOUNDS | TOP2B, DDB1, TOP1 | TDP1 103/4885TDP2 255/4885NSD2 391/4885 |
| US-20110034718-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRIN COMPOUND | CBR3, ACSL3, CCNL2 | TDP1 4826/4885TDP2 4808/4885NSD2 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.